Research location

Sakai

Osaka, Japan

Published trials113

Site observations119

Linked trials published113

Page1 / 3

Research activity in Sakai

Osaka, Japan

CureCurrent currently publishes aggregate city-level research activity for this location: 113 trials and 119 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Sakai

113 linked trials · page 1 of 3

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerNCT07617337 · 2026-07-24 · 1 site observation

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart FailureNCT07397650 · 2026-05-11 · 1 site observation

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationNCT07566052 · 2026-04-28 · 1 site observation

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)NCT07361497 · 2026-03-16 · 1 site observation

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT07363694 · 2026-02-11 · 1 site observation

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerNCT07288177 · 2026-01-30 · 1 site observation

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)NCT07359846 · 2026-01-20 · 1 site observation

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT07179380 · 2026-01-07 · 1 site observation

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229 · 2025-12-02 · 1 site observation

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)NCT07218146 · 2025-11-30 · 1 site observation

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)NCT07190248 · 2025-10-08 · 1 site observation

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCERNCT07107490 · 2025-10-08 · 1 site observation

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)NCT07144280 · 2025-09-29 · 2 site observations

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)NCT07060807 · 2025-07-21 · 1 site observation

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)NCT07011732 · 2025-07-10 · 1 site observation

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe AsthmaNCT06977581 · 2025-05-20 · 1 site observation

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid TumorsNCT06914128 · 2025-03-21 · 1 site observation

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06760819 · 2025-02-13 · 1 site observation

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2NCT06694012 · 2024-11-01 · 1 site observation

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)NCT06623422 · 2024-10-21 · 1 site observation

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%NCT06561386 · 2024-10-07 · 1 site observation

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)NCT06585787 · 2024-09-26 · 1 site observation

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 · 2024-07-31 · 1 site observation

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsNCT06427941 · 2024-07-23 · 1 site observation

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · 2024-04-03 · 1 site observation

A Study of KK2269 in Adult Participants With Solid TumorsNCT06266299 · 2024-01-18 · 2 site observations

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31 · 1 site observation

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18 · 1 site observation

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)NCT05980949 · 2023-07-11 · 1 site observation

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)NCT05099172 · 2021-10-25 · 1 site observation

A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)NCT06698042 · 2024-11-21 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerNCT06012435 · 2024-02-21 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)NCT06099782 · 2023-12-26 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)NCT06077760 · 2023-12-06 · 1 site observation

ACTIVE_NOT_RECRUITING

Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyNCT06033833 · 2023-09-05 · 1 site observation

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)NCT05609968 · 2023-02-06 · 1 site observation

ACTIVE_NOT_RECRUITING

Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With SchizophreniaNCT05368558 · 2022-08-18 · 1 site observation

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep ApneaNCT05412004 · 2022-06-21 · 1 site observation

An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart FailureNCT05297409 · 2022-05-21 · 1 site observation

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)NCT05239728 · 2022-03-15 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07 · 1 site observation

ACTIVE_NOT_RECRUITING

A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving DurvalumabNCT04884269 · 2021-08-11 · 1 site observation

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)NCT04956692 · 2021-08-05 · 1 site observation

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenNCT04940065 · 2021-06-30 · 2 site observations

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.